# EDGAR Filing Document

**Accession Number:** 0001984047
**File Stem:** 0001193125-25-337075
**Filing Date:** 2025-12
**Character Count:** 11800
**Document Hash:** d04861fcbc7bfa881ee68cb1ee3df809
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-337075.hdr.sgml**: 20251230

**ACCESSION NUMBER**: 0001193125-25-337075

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251230

**DATE AS OF CHANGE**: 20251230

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Minerva Neurosciences, Inc.
- **CENTRAL INDEX KEY:** 0001598646
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 260784194
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88240
- **FILM NUMBER:** 251614253

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 617-600-7373

**MAIL ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Boehringer AG
- **CENTRAL INDEX KEY:** 0001984047

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** BINGER STRABE 173
- **CITY:** INGELHEIM AM RHEIN
- **STATE:** 2M
- **ZIP:** 55216
- **BUSINESS PHONE:** 496132770

**MAIL ADDRESS:**
- **STREET 1:** BINGER STRABE 173
- **CITY:** INGELHEIM AM RHEIN
- **STATE:** 2M
- **ZIP:** 55216

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_i.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**MINERVA NEUROSCIENCES, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**603380106**

*(CUSIP Number)*

**Boehringer Ingelheim Int. GmbH**<br>Binger Strasse 173<br>Attn: Head of Corp. Legal Gov. and M&A<br>Ingelheim am Rhein 2M 55216<br>49613277171954

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/23/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **603380106** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Boehringer AG** | Name of reporting person<br>**Boehringer AG** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1500225.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1500225.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1500225.00** | Aggregate amount beneficially owned by each reporting person<br>**1500225.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.4%** | Percent of class represented by amount in Row (11)<br>**3.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1)	Securities reflected in rows 8, 10 and 11 comprised of 1,275,000 shares of Common Stock (as defined herein) and an additional 225,225 shares of Common Stock receivable upon exercise of a Pre-Funded Warrant (as defined herein). All securities are held directly by Boehringer Ingelheim International GmbH ("International GmbH"), a wholly owned indirect subsidiary of C. H. Boehringer Sohn AG & Co. KG ("Parent"). Boehringer AG (the "GP") is the General Partner of Parent. The GP and International GmbH may each be deemed to have shared voting and dispositive power over all of the securities.
(2)	Percentage in row 13 based on (i) 43,274,398 shares of Common Stock issued and outstanding as of December 23, 2025, as reported by Minerva Neurosciences, Inc. (the "Issuer") in its Registration Statement on Form S-3 filed on December 23, 2025 and (ii) 225,225 shares of Common Stock issuable within 60 days of the date hereof upon the exercise of a Pre-Funded Warrant held by International GmbH.

| **CUSIP No.** | **603380106** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Boehringer Ingelheim International GmbH** | Name of reporting person<br>**Boehringer Ingelheim International GmbH** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1500225.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1500225.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1500225.00** | Aggregate amount beneficially owned by each reporting person<br>**1500225.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.4%** | Percent of class represented by amount in Row (11)<br>**3.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1)	Securities reflected in rows 8, 10 and 11 comprised of 1,275,000 shares of Common Stock and an additional 225,225 shares of Common Stock receivable upon exercise of a Pre-Funded Warrant. All securities are held directly by International GmbH, a wholly owned indirect subsidiary of Parent. The GP is the General Partner of Parent. The GP and International GmbH may each be deemed to have shared voting and dispositive power over all of the securities.
(2)	Percentage in row 13 based on (i) 43,274,398 shares of Common Stock issued and outstanding as of December 23, 2025, as reported by the Issuer in its Registration Statement on Form S-3 filed on December 23, 2025 and (ii) 225,225 shares of Common Stock issuable within 60 days of the date hereof upon the exercise of a Pre-Funded Warrant held by International GmbH.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
MINERVA NEUROSCIENCES, INC.

**(c) Address of Issuer's Principal Executive Offices:**
1500 District Avenue, Burlington, MA, 01803

This Amendment No. 1 ("Amendment No. 1") amends as set forth below a statement on Schedule 13D filed by the Reporting Persons (as defined herein) on July 7, 2023 (the "Original Filing") with respect to shares of Common Stock and a pre-funded warrant to purchase the same (the "Pre-Funded Warrant"). On December 23, 2025, each of the Reporting Persons ceased to be a beneficial owner of more than 5% of the Common Stock as a result in the increase in the shares of Common Stock outstanding. The filing of this Amendment No. 1 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

**Item 4. Purpose of Transaction**

There are no material updates to the Original Filing.

**Item 5. Interest in Securities of the Issuer**

**(a)**
GP                                                        1,500,225                  3.4%
International GmbH                              1,500,225                  3.4%

**(b)**
(i)	Sole power to vote or to direct the vote
GP                                                                                           0
International GmbH                                                                 0

(ii)	Shared power to vote or to direct the vote
GP                                                                        1,500,225
International GmbH                                              1,500,225

(iii)	Sole power to dispose or to direct the disposition of
GP                                                                                          0
International GmbH                                                                0

(iv)	Shared power to dispose or to direct the disposition of
GP                                                                                           1,500,225
International GmbH                                                                 1,500,225

International GmbH is a wholly owned indirect subsidiary of C. H. Boehringer Sohn AG & Co. KG ("Parent"). The GP is the General Partner of Parent. The GP and International GmbH may each be deemed to have shared voting and dispositive power over all of the securities.

None of the individuals listed on Schedule I beneficially own any Common Stock.

**(c)**
Neither the Reporting Persons nor any of the individuals listed on Schedule I have effected any transactions in the Common Stock during the past sixty days. The decrease in percentage of beneficial ownership reported in this Amendment No. 1 results solely from an increase in the number of outstanding shares of Common Stock.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

There are no material updates to the Original Filing.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Boehringer AG

**Signature:** /s/ Arjan van der Oort

**Name/Title:** Arjan van der Oort, Registered Manager (Prokurist)

**Date:** 12/30/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Boehringer Ingelheim International GmbH

**Signature:** /s/ Dana Leskova

**Name/Title:** Dana Leskova, Registered Manager (Prokurist)

**Date:** 12/30/2025